Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 588 participants.

Also called NCT01615198

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 588 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01615198
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Hong Kong SAR China, Japan, Philippines, South Korea, Taiwan, Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01615198. Randomized; double masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2015-08-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Olmesartan
Intervention (Drug)
Placebo
Intervention (Drug)
LCZ696
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01615198
Content hash
13e19005678a33722e03b3bf54d3efc2ac261b35c37f58f6e3cfbcea80a650b2